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1. Introduction 
Coupling factor 1 (CF,), ‘isolated from chloroplasts, 
is believed to be the protein which catalyzes the syn- 
thesis of ATP in photophosphorylation [ 11. The 
latent, isolated protein exhibits ATPase activity when 
properly activated by heat [2], trypsin [3], or dithio- 
threitol [4]. 
It has been shown that the protein contains multi- 
ple nucleotide binding sites [5-l 11. However, the 
relationship between the ‘tight’ nucleotide binding 
sites (Kd CL PM) in the isolated, latent or activated 
protein and the ATPase catalytic site(s) is unclear. It 
has been argued that the rate of association of nucleo- 
tides such as EADP, eAMP-P(NH)P [5] or formycin di- 
and triphosphate [ 1 l] with the tight sites of the latent 
enzyme is too slow for such sites to be involved in 
catalytic turnover. However, it was reported [ 1 l] that 
the association of nucleotides with the activated 
enzyme is much faster and suggested that this change 
in association kinetics may reflect the activation of 
the ATPase. The binding site for the ATP analogue 
AMP-P(NH)P, exposed upon heat activation of CF1, 
has been suggested as the active site for the ATPase, 
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whereas the other tight binding site(s) are regulatory 
[51. 
Here we report on the interaction of energy trans- 
fer inhibitors with the adenine nucleotide binding 
sites. Some energy transfer inhibitors, e.g., phlorizin, 
tentoxin and quercetin, are found to stimulate the 
binding of adenine nucleotides to CF1 by exposing 
additional binding site(s) on the protein. On the other 
hand, dicyclohexylcarbodiimide (DCCD) inhibits the 
ATPase activity (of activated CF1) and eliminates one 
of the nucleotide binding sites which is exposed by 
the activation of the latent CF,-ATPase or in the 
presence of tentoxin. These results suggest hat the 
binding site for adenine nucleotides, exposed by the 
activation of CFI dr the presence of energy transfer 
inhibitors, may be the active site for ATP hydrolysis. 
2. Materials and methods 
Chloroform-released CF1 was isolated and purified 
as in [ 11,141. The protein was stored as a suspension 
in 50% saturated ammonium sulfate containing 1 mM 
EDTA, 4 mM ATP, and 20 mM tricine-NaOH (pH 
7.1). Prior to use, ammonium sulfate and readily 
exchangeable nucleotides were removed by chromatog- 
raphy on Sephadex G-50 (1 .O X 10 cm) equilibrated 
with 1 mM EDTA and 40 mM tricine-NaOH (pH 8.0). 
The ATP, ADP, and AMP content of the latent and 
DTT-activated proteins was examined by the methods 
in [15]. The enzyme, after gel filtration, contained 
about 1 mol ADP/mol CF1, 0.16 mol ATP/mol CF1 
and no detectable AMP. Disc-gel electrophoresis 
demonstrated that the protein was > 97% pure. Pro- 
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tein concentration was determined as in [ 161 with 
bovine serum albumin as a standard and assuming 
mol. wt 325 000 for CFI [17]. The Ca2’-ATPase 
activity of the protein was determined as in [ 141 
after heat [2] or dithiothreitol [4] activation. 
Radioactive nucleotides, [2,8-‘H]ADP and [8-3H]- 
AMP-POP, were purchased from New England 
Nuclear and [2,S-3H] from ICN. [T-~?]ATP was 
prepared from ADP and [3?]phosphate by photo- 
phosphorylation and was purified as in [ 181. 
The binding of labeled adenine nucleotides to 
CFI (0.2 mg/ml) was measured by the chromatog- 
raphy-centrifugation procedure in [ 191 except hat 
the Sephadex G-50 fine was equilibrated in 20 mM 
tricine-NaOH @H 8.0). incubation mixtures for the 
binding assay contained in 0.22 ml total vol., 50 mM 
tricine-NaOH (pH 8.0), 25 mM NaCl and 10 /.LM 
labeled nucleotide (at -3 X 10’ cpm/nmol), and 
other reagents as indicated in the legends. After 
incubation at 37% for 30 min, 0.1 ml sample was 
loaded onto a 1 ml packed Sephadex G-50 column 
and centrifuged for 2 min at -1200 X g. Scintillation 
cocktail [ 121 5 .O ml, was added to the column efflu- 
ent and the radioactivity was measured in a Beckman 
LSlOO liquid scintillation counter. 
3. Results 
The effects of tentoxin, phlorizin, and quercetin 
on the binding of ADP or ATP to CF, are shown in 
table 1. Under the conditions used (the absence of 
Table 1 
The effect of several energy transfer inhibitors on ADP and 
ATP binding to isolated, latent CF, 
Inhibitor mol AdN bound/CF, 
ADP ATP 
None 0.37 0.63 
Phlorizin (2.5 mM) 0.63 1.01 
Phlorizin (10 mM) 0.94 n.d. 
Tentoxin (20 PM) 0.65 1.25 
Tentoxin (200 rM) 1.15 1.36 
Quercetin (50 rM) 0.52 1.02 
Quercetin (200 rM) 0.62 0.96 
n.d. = not determined 
Adenine nucleotide binding was measured as in section 2 
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divalent cations), all of the inhibitors increase the 
total amount of adenine nucleotide bound to CFI 
2-3-fold. Similar esults have been reported for ten- 
toxin [12,13]. 
Figure 1 shows the correlation between the phlori- 
zin stimulation of ATP binding to the soluble cou- 
pling factor and the inhibition of the ATPase activity. 
A linear relationship between the increase in the total 
bound nucleotide and the inhibition of the ATPase 
activity is obtained (fig.1, inset). 
Heat activation of the latent CF1 has been the cause 
reported [S] for the appearance of an additional binding 
site for the ATP analogue AMP-P(NH)P. This observa- 
tion has been confirmed for the DTT-activated CFI 
(table 2). The effect, however, is most significant in 
the absence of divalent cations (0.55 compared to 
2.38 AMP-P(NH)P/CF,). Table 2 also shows that 
DTT-activation of CF1 increases the binding of not 
only AMP-POP, but also of ADP and ATP. 
The relationship between the site(s) exposed by 
DTT-activation of CF1 and the site(s) exposed in the 
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Fig. 1. Correlation between the phlorizin inhibition of the 
ATPase activity and stimulation of ATP binding. Conditions 
for [ ‘H]ATP binding or ATPase activity of the heat activated 
enzyme were as in section 2. 
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Table 2 
Comparison between the effects of DTT-activation, Mg* and phloriain on the binding 
of different labeled nucleotides 
Nucleotide mol AdN bound/CF, 
Latent CF, DTT-activated CF, 
Additions: None Mgp Phlorizin None Mg* PhlOIiZh 
[sH]ADP 0.50 1.39 0.89 0.99 1.18 1.44 
[ ‘H]ATP 0.89 1.43 1.51 2.15 2.07 2.30 
[ 3H]AMP-P(NH)P 0.55 1.76 0.61 2.38 2.34 2.29 
[+sP]ATP 0.52 0.99 0.95 1.18 0.96 1.14 
CF, was activated by incubation for 30 min at 37°C with 50 mM DTT (pH 8.0). DTT was 
removed by the centrifugation-chromatography procedure [181. Conditions for nucleotide 
binding were as in section 2 except that the reaction mixtures contained 5 mM phlorizin 
or 2 mM MgCl, where indicated _ 
presence of an energy-transfer inhibitor, phlorizin, 
is also shown in table 2. Both Mg” and phlorizin 
increase the binding of all of the nucleotides to the 
latent enzyme but have only a marginal effect on 
the binding to the DTT-activated CFr. A combina- 
tion of both Mg* and phlorizin does not further 
increase the binding to the latent enzyme (data not 
shown). These results uggest that the nucleotide 
binding site(s) exposed by Mg* or energy transfer 
inhibitors is the same site which is exposed by the 
activation of CFr to an active ATPase. However, the 
effect of DTT-activation on nucleotide binding per- 
sists even after removal of DTT, whereas the stimu- 
latory effect of energy transfer inhibitors or Mgv 
requires their continual presence during the binding 
assays (data not shown). 
The number of ADP binding site(s) and the disso- 
ciation constants obtained with latent CFr under 
different conditions are summarized in table 3. The 
latent enzyme has a single, strong binding site with 
Kd -0.7 PM. Under similar conditions, a single 
binding site per CFr was also found [ 10,201. How- 
ever, in the presence of either Mg’+, tentoxin, or 
pblorizin the number of the ADP binding sites 
increases to 3 and the affinity of the enzyme for 
ADP decreases. DTT activation of CFr increases the 
number of ADP binding sites to 2 or 3. (V.S., B.R.S., 
submitted). The apparent increase in the number of 
ADP binding sites by the above compounds or by 
the activation of the enzyme might be due to an 
acceleration of ADP incorporation into CFr and/or 
to a stabilization of the pre-bound nucleotides to 
loose binding sites and which are easily dissociated 
from the enzyme during the binding assay (Sephadex 
gel chromatography). 
We have shown (V.S., B.R.S., submitted) that, 
under certain conditions, DCCD interacts with soluble 
CFr to inhibit the ATPase activity. Figure 2 shows 
that DCCD inactivation of the CFr-ATPase also 
results in the inhibition of ADP binding to the DTT- 
activated enzyme. Maximal inhibition of the ATPase 
activity is accompanied by the elimination of one 
ADP binding site. A linear relationship between the 
loss of ATPase activity and the disappearance of the 
ADP binding site is observed (fig.2, inset). Table 4 
shows that DCCD-modification of CFr inhibits not 
only the ADP binding to the DTT-activated CFr, but 
Table 3 
Dissociation constants (Kd) and numbers of binding sites (n) 
for the binding of ADP to CF, 
Additions n Kd 
(PM) 
None 1 0.7 
MgCJ (2 mM) 3 1.9 
Tentoxm (350 PM) 3 1.5 
Phlorizin (9 mM) 3 2.6 
Latent CF, was incubated for 30 min at 37’C with varying 
concentrations of [ 3H]ADP. Incubation mixtures contained 
50 mM tricine-NaOH (pH 8.0) and 2.5 mM NaCl. Kd and n 
were calculated from Scatchard plots 
415 
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Fig.2. Correlation between the DCCD inhibition of the 
ATPase activity and ADP binding. DTT-activated CF, was 
obtained as in table 2. The activated enzyme was incubated 
for 30 min at 37°C with the indicated concentrations of 
DCCD in 100 mM MOPS buffer (pH 7.0). Ahquots of 5 ~1 
and 50 ~1 were assayed for ATPase activity and ADP binding, 
respectively. The % inhibition of ADP binding by DCCD 
(inset) was calculated for the values after subtraction of 
the DCCD-insensitive portion of the binding (0.35 ADP 
bound/F,). 
also the tentoxin stimulation of ADP binding to the 
latent CFr. DCCD only slightly affects the binding 
of ADP to the latent CFr. 
4. Discussion 
It is apparent that the interaction of soluble CF, 
with the energy transfer inhibitors, tentoxin, quer- 
cetin, and phlorizin increases the binding of adenine 
nucleotides to the enzyme in a manner similar to 
DTT-activation of the ATPase or heat activation [5]. 
The question that arises, of course, is how the adenine 
nucleotide binding site(s) exposed by these treatments 
relates to: 
(i) The active site of the ATPase and/or 
(ii) The so-called ‘tight’ binding site of membrane- 
bound CFr whose nucleotides can be exchanged 
upon energization of the thylakoid membrane 
(see [21]). 
We have suggested that the tightly bound ADP occu- 
pies either the active or a regulatory site for ATPase 
activity [22]. 
We have reported [ 12,131 that tentoxin induces 
an exchange of tightly bound ADP for medium ADP 
with the soluble protein. If this adenine nucleotide 
binding site is filled with a radioactively labeled ade- 
nine nucleotide and the CFr reconstituted with 
partially resolved thylakoid membranes, the bound 
adenine nucleotide exchanges with medium nucleo- 
tides upon energization of the membrane. Therefore, 
we have argued that the ‘tight’ binding site exposed 
either by tentoxin (with the soluble coupling factor) 
or light (with the membrane-bound protein) are 
identical [ 12,131. This, however, is probably not the 
only change in the properties of the binding sites 
Table 4 
Effect of DCCD modification of CF, on ADP binding to the latent and 
activated proteins 
CF, preparation mol ADP bound/CF , 
- Tentoxin + Tentoxin 
ATPase activity 
(pmol Pi released/mg 
protein/min) 
Latent 
DCCDmoditled, 
latent 
DTT-activated 
DCCD-modified, 
DTT-activated 
0.89 2.08 2.09 
0.65 1.15 0.1 
1.78 2.13 13.8 
0.76 1.40 1.0 
DCCDmodified CF, wasobtained as in fig.2, and DTTactivated CF, as in table 2. 
ATPase activity and ADP binding were measured as in section 2. Tentoxin was 
200 WM 
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induced upon activation of the coupling factor. 
An analysis of table 2 shows that, although energy 
transfer inhibitors induce adenine nucleotide binding 
to CF,, they are not as effective as DTT-activation. 
The binding of adenine nucleotides to DTT-activated 
CFr is not influenced by energy transfer inhibitors 
(except DCCD, see discussion below). This result sug- 
gests that the binding sites exposed by DTT activa- 
tion of CFr encompass the binding sites exposed by 
energy transfer inhibitors. 
There are quantitative differences in the absolute 
level of binding depending on thenature of the 
nucleotide, i.e., ATP or AMP-P(NI-I)P’versus ADP 
and even [3H]ATP versus [Y~~P]ATP (table 3). In 
order to explain these differences, we have suggested 
the following model. 
I 
CFr - ADP 
pi ATP 
Jk 
(3) (I) 
ADP 
\ 
(2) ADP 
,CFr f--------- CF, . . . ATP 
Pi ’ 
III II 
State I represents a tight complex between CFr and 
ADP and is the stable form of the isolated, purified 
CFi [‘l 1,23-251. The tightly bound ADPis exchanged 
with ATP in the medium under certain conditions 
[ 12,13,20] to form state II. The ATP in the CFr-ATP 
complex is rapidly hydrolyzed to form bound Pi 
and ADP (state III) (table 2). The increase in nucleo- 
tide binding by the activation of CF1 could be due to 
an acceleration of reaction (1) or, in the case of 
energy transfer inhibitors, inhibition of reaction (2). 
This suggestion is supported by the observation that, 
upon activation of CFr, a marked increase in the rate 
of nucleotide binding is observed [ 111. Accordingly, 
we find that when the DTTactivated enzyme is 
incubated with [‘H]ATP or [3H]AMP-P(NH)P, 2 2 
binding sites are fdled. We suggest that one of these 
is the ATPase active site (AMP-P(NH)P is a strong 
competitive inhibitor of the ATPase [ 51) and the 
other sites are binding sites that may have a regula- 
tory function. On the other hand, incubation of the 
activated enzyme with [3H]ADP or [r_?]ATP 
reveals 1 less site. We suggest that the binding of 
[3H]ADP under these conditions is not to the active 
site, but rather to a regulatory site. ADP has been 
shown [26] to be an allosteric inhibitor of the 
ATPase which would suggest binding to a site other 
than the active site. [T-~%‘]ATP binds to both types 
of sites, but because the ATPase is active, the bound 
““Pi s lost and the binding to the active site is not 
seen. Thus, the binding induced by energy transfer 
inhibitors and activation of the ATPase is a mixture 
of exchange induced both at the active site and regu- 
latory site(s). 
Treatment of the protein with DCCD causes acon- 
commitant loss of the activity of the enzyme and one 
adenine nucleotide binding site. It is tempting to 
speculate that the loss of activity by DCCD modifica- 
tion of CFt is due to an inhibition of nucleotide 
exchange at the tight-binding site which has been sug- 
gested to be the active site. However, it is not yet 
clear whether the lost binding site is the ATPase 
active site or a regulatory site. This is particularly 
important because chemical modification of only the 
a-subunit of Fi-ATPase causes afull inactivation of 
the enzyme [27], whereas the active site is thought 
to be on the &subunit [28]. Clearly, there is an inter- 
action between the 2 types of binding sites. The 
effect of DCCD treatment on the activities of the 
Fr-ATPase has been reported [29] and for CF, has 
been demonstrated and detailed (V.S., B.R.S., 
submitted). DCCD binds covalently to the &subunit 
of CFr and the inhibition of the hydrolytic activity 
parallels the loss of 1 nucleotide binding site. These 
findings upport he location of the active site for 
ATPase activity on the &subunit of CFr [is]. DCCD 
modification of CFr can be used to provide impor- 
tant insights into the role and function of 1 adenine 
nucleotide binding site of CFr, both in the soluble 
and membrane-bound CFr. 
417 
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